DSGN (Design Therapeutics) Moat Score: 2/10 (As of Jul. 06, 2026)


DSGN Design Therapeutics Inc DSGN
33 GF Score
Price $15.65
! 2 Warning Signs
View Full Analysis

What is Design Therapeutics Moat Score?

Design Therapeutics DSGN +6.68% 33 Moat Score is 2 as of Jul. 06, 2026. GuruFocus rates DSGN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, Design Therapeutics ranks better than 58.28% on this metric.

Design Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Design Therapeutics has No Moat: Design Therapeutics Inc lacks significant market leadership or customer switching costs. The company does not have a strong brand or durable cost advantages. Its intellectual property is not yet proven to provide a sustainable competitive edge, and there are no significant regulatory barriers or exclusive licenses that protect its market position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Design Therapeutics might have No Moat - Very weak/transient advantages.

Design Therapeutics  (NAS:DSGN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Design Therapeutics Moat Score Related Terms

DSGN vs SPRY, GERN, PHAT: Moat Score Comparison

For the Biotechnology subindustry, Design Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Design Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's Moat Score falls into.


DSGN
33GF Score
Design Therapeutics Inc DSGN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Design Therapeutics (DSGN) has a Moat Score of 2 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Design Therapeutics ranks #582 out of 1395 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Design Therapeutics' Moat Score too high?
Design Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Design Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Design Therapeutics ranks #582 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Design Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Design Therapeutics' Moat Score compare to SPRY and GERN?
According to the Biotechnology industry distribution chart, Design Therapeutics ranks #582 out of 1395 companies for Moat Score. This puts Design Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Design Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Design Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Design Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Design Therapeutics stock overvalued right now?
Design Therapeutics (DSGN) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Design Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Design Therapeutics (DSGN), the current Moat Score is 2 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Design Therapeutics Business Description

Address 6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
33GF Score

Get the complete analysis for DSGN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.65
Price